Robin Sitver

Robin Sitver is Vice President, Global Business Development, Diabetes Care at Johnson & Johnson. She is responsible for leading strategic business development initiatives for the diabetes business including acquisitions, divestitures and strategic alliances. Previously, she was Global Head, Licensing and Strategic Initiatives for Johnson & Johnson Consumer Inc where she was primarily responsible for leading all aspects of major M&A transactions including divestitures. She is also responsible for the trademark licensing strategy and implementation. In addition, she has led licensing, acquisition, divestitures, strategic alliances and other business development transactions for the global Topical Health, Intimate Health and Personal Care businesses.

Robin has completed over sixty license, acquisition and divestiture transactions in her career. Since joining J&J in 2006, she has divested 55 businesses in 28 transactions worth over $5.6 billion. She recently led the $2.1 billion transaction to divest Lifescan to Platinum Equity. She also led the divestitures of Splenda to Heartland, Tucks to Blistex, REACH to LG, Rembrandt to Ranir and KY to Reckitt- Benckiser. She started her career at Pfizer in 1979 in the Pharmaceuticals Division and held a variety of global strategic leadership positions in finance, systems, marketing and operations in the Pharmaceuticals and Animal Health Divisions before joining Pfizer Consumer Healthcare, which was acquired by J&J in 2006.